ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022
Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is It All About ME1?
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Knowledge mapping of ferroptosis in sarcoma: a bibliometric and bioinformatics analysis (2012-2023).Discover oncology · 2025Article
- Cross-disease biomarker identification reveals shared diagnostic biomarkers for IVDD and NAFLD via bulk and single-cell RNA sequencing.Frontiers in molecular neuroscience · 2025Article
- Malic Enzyme 1 as a Novel Anti-Ferroptotic Regulator in Hepatic Ischemia/Reperfusion Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Understanding metabolic dependencies and their therapeutic vulnerabilities is key to precision oncology. Malic enzyme 1 (ME1) is frequently overexpressed in cancers with protumorigenic effects. In contrast, consistent loss of ME1 expression in synovial sarcoma compared with other sarcomas indicates a unique ferroptosis liability for precision therapy in this form of cancer. See related article by Brashears et al., p. 3573.
Indexed as
Identifiers
35727698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.